Science Journal of Public Health

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Effect of PROLCARMIV on Management of Non-Communicable Diseases Among People Living with HIV in Busia, County Hospital-Kenya

Good Nutrition optimizes benefits of ART and increases treatment adherence, both prolong lives of PLHIV (NASCOP, 2014), without proper care and management it exposes them to non-communicable diseases (NCDs). Key objective; To determine the effect of food-based nutrition intervention on the management of NCDs among PLHIV in Busia. Design was experimental using randomized control trial approach. Control group- 30 subjects fed on Plumpy ‘nut while treatment group – 30 subjects fed on Power Porridge (PROLCARMIV), for 60 days. Subjects purposively selected from the Comprehensive Care Clinic (CCC) in Busia County referral hospital- Kenya, further randomly selected using simple random sampling, assigned equally to each group. Data collected using a structured questionnaire analyzed using Social Package for Statistical Sciences version 26. Prevalence of NCDS; 75.5% hypertension; 15.6% Diabetes and 8.9% heart disease; post-intervention BMI for intervention group increased; Laboratory analyses; Hb post–intervention results; mean levels were higher in intervention group (M=13.62, SD=2.69) p-value = 0.487 compared to control group (12.69, SD=1.24), p value= 0.471. RBS were higher in control group (5.96, SD=1.70), p value= <0.001, intervention group (M=5.79, SD=1.02), p-value = <0.001. Post-intervention liver function test; TB, AST, and ALT showed higher SD indicating variability. Lipid profile; showed TC mean (4.39 (0.95) for control group; a mean 3.78 (0.94) intervention group: p=0.017; HDL -control group mean 1.58 (0.57): 1.14 (0.53) intervention group p=0.036: TG - control group mean 1.50 (0.50): intervention group p= 0.017: mean 1.14: (0.46): LDL mean 2.26 (0.66) control group: 1.43 (0.42): intervention group p= 0.041: all exhibited significant decreases. Kidney function tests; no significant differences between the two groups. Conclusion; Compliance for PROLCARMIV; 82.5%, attracting uptake of CCC services. PROLCARMIV can manage NCDs among PLHIV, answering the alternative hypothesis, this would inform Policy.

Food-Based Nutrition Intervention, HIV, NCDs, PLHIV, PROLCARMIV, Power Porridge

APA Style

Ruth Wamatuba Akelola, Wamukoya Edwin, Situma Jane. (2023). Effect of PROLCARMIV on Management of Non-Communicable Diseases Among People Living with HIV in Busia, County Hospital-Kenya. Science Journal of Public Health, 11(5), 174-185. https://doi.org/10.11648/j.sjph.20231105.14

ACS Style

Ruth Wamatuba Akelola; Wamukoya Edwin; Situma Jane. Effect of PROLCARMIV on Management of Non-Communicable Diseases Among People Living with HIV in Busia, County Hospital-Kenya. Sci. J. Public Health 2023, 11(5), 174-185. doi: 10.11648/j.sjph.20231105.14

AMA Style

Ruth Wamatuba Akelola, Wamukoya Edwin, Situma Jane. Effect of PROLCARMIV on Management of Non-Communicable Diseases Among People Living with HIV in Busia, County Hospital-Kenya. Sci J Public Health. 2023;11(5):174-185. doi: 10.11648/j.sjph.20231105.14

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. WHO, 2022. World Health Organization Statistics (2022).
2. WHO, 2013. World Health Statistics 2013.
3. WHO. Global Health Observatory Data, 2018. NCD mortality and morbidity. 201 [Available from: http://www.who.int/gho/ncdmortality morbidity/en/./
4. World Health Organization, 2014. Non-communicable diseases country profiles 2014. Geneva, Switzerland: World Health Organization; 2014. [Google Scholar].
5. Fathima et al. 2022. Nutritional Aspects of People Living with HIV (PLHIV) Amidst COVID-19 Pandemic: An Insight.
6. NASCOP, 2014. Kenya Nutrition and HIV guidelines (2014).
7. Mathebula et al., 2020. The prevalence of selected non-communicable disease risk factors among HIV patients on anti-retroviral therapy in Bushbuckridge sub-district, Mpumalanga province.
8. Chhoun et al., 2017. Non-communicable diseases and related risk behaviors among men and women living with HIV in Cambodia: findings from a cross-sectional study.
9. WFP/FAO, 2008. WFP /FAO Rapid Food Security Assessment – June/July 2008.
10. NACC, 2017. Kenya HIV estimates.
11. Sanjay et al. 2014. International table of glycemic index and glycemic load values: 2002 World Cancer Research Fund International, 2014.
12. Leitzmann, 2016. Characteristics and Health Benefits of Phytochemicals.
13. Crozier A., 2007). An evaluation of flavonoids and phenolic compounds in commercial fruit juices and juice drinks. Journal of Agricultural and Food Chemistry 55, 3148–3157 (HN).
14. MOH, 2017. Food-based dietary guidelines – Kenya.
15. Achwoka, D., Waruru, A., Chen, T. et al (2019). Non-communicable disease burden among HIV patients in care: a national retrospective longitudinal analysis of HIV treatment outcomes in Kenya, 2003-2013. BMC Public Health 19, 372 (2019).
16. Bloomfield GS, Alenezi F, Barasa FA, Lumsden R, Mayosi BM, Velazquez EJ. Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. 2015; 3: 579–90.
17. Divala OH, Amberbir A, Ismail Z et al. 2016. The burden of hypertension, diabetes mellitus, and cardiovascular risk factors among adult Malawians in HIV care: consequences for integrated services. BMC Public Health 16: 1243.
18. Edwards JK, Bygrave H, Van den Bergh, Kizito W, Cheti E, Kosgei RJ et al. HIV with non-communicable diseases in primary care in Kibera, Nairobi, Kenya: characteristics and outcomes. Trans R Soc Trop Med Hyg. 2015; 109 (7): 440-6.
19. Eugenin EA, Morgello S, Klotman ME, Mosoian A, Lento PA, Berman JW, et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol. 2008; 172 (4): 1100–11.
20. Faul, Erdfelder, Buchner, & Lang, 2009. Statistical Power Analyses. Using G*Power 3.1: Tests for Correlation and Regression Analyses.
21. Matthew Hing, Risa M Hoffman, Juliet Seleman, Florence Chibwana, Daniel Kahn and Corrina Moucheraud (2019). ‘Blood pressure can kill you tomorrow, but HIV gives you time’: Illness perceptions and treatment experiences. 2019.
22. Ministry of Health. Kenya National Strategy for the prevention and control of non-communicable diseases 2015 - 2020. Nairobi: Ministry of Health, 2015. [Google Scholar].
23. National AIDS and STI Control Programme (NASCOP), Preliminary KENPHIA 2018 Report. Nairobi: NASCOP; 2020.
24. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005; 165 (10): 1179–84.
25. Gobbens RJ. Associations of ADL and IADL disability with physical and mental dimensions of quality of life in people aged 75 years and older. PeerJ. 2018 Aug 9; 6: e5425. doi: 10.7717/peerj.5425. PMID: 30123720; PMCID: PMC6087617.